Bar

Bar

Our Approach
Therapeutic Focus
About Us
News
Join Us

News

Press Releases

July 14, 2020

Vor Biopharma Appoints Dr. Christopher Slapak as Chief Medical Officer

July 7, 2020

Vor Biopharma Closes $110 Million Series B Financing

May 26, 2020

Vor Biopharma Adds to Leadership Team with Appointment of Chief Financial Officer

April 7, 2020

Vor Biopharma Appoints Dr. Robert Pietrusko as Chief Regulatory and Quality Officer

January 7, 2020

Vor Biopharma Expands Leadership Team with Chief Legal Officer and Vice President of People

November 21, 2019

Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer

Load More Posts

Media Coverage

July 22, 2019

“The Promise and Price of Cellular Therapies”

The New Yorker

June 5, 2019

“Meet the Man Who’s Taking On the Emperor of All Maladies: Cancer”

J&J Innovation

February 14, 2019

“Vor Biopharma raises $42M in Series A round to advance AML cell therapy toward clinic”

MedCity News

May 17, 2018

“Beyond B Cells: How Vor Biopharma’s Platform Could Eliminate On-Target Toxicity for CAR-Ts”

BioCentury

100 Cambridgepark Dr, Suite 400, Cambridge, MA 02140

P: 617-655-6580

Email

Contact Us
Privacy Policy
Terms of Use

© 2020 Vor Biopharma. All rights reserved.